-
Enzalutamide, sold
under the
brand name Xtandi, is a
nonsteroidal antiandrogen (NSAA)
medication which is used in the
treatment of
prostate cancer. It...
-
hepatic impairment is unknown. Two 2020 meta-analyses
reported that
enzalutamide and
apalutamide seemed to be more
effective than
darolutamide in improving...
-
visual disturbances, and
alcohol intolerance with nilutamide.
Unlike enzalutamide,
bicalutamide is not ****ociated with
seizures or
related central side...
-
metastatic castration-resistant
prostate cancer (mCRPC),
which the NSAA
enzalutamide and the
androgen synthesis inhibitor abiraterone acetate are used to...
-
similar activity to that of
enzalutamide and, with
enzalutamide therapy,
circulates at
similar concentrations to
those of
enzalutamide at
steady state. N-Desmethylenzalutamide...
-
androgen blockade (also
known as
complete or
maximal androgen blockade).
Enzalutamide, apalutamide, and
abiraterone acetate are
specifically approved for use...
- 2024, the
European Commission approved talazoparib in
combination with
enzalutamide for the
treatment of
metastatic castration-resistant
prostate cancer...
-
antagonist of the AR
reportedly comparable to the
potent antagonist enzalutamide. However, the
initial 5α-reduced
metabolite of D4A, 3-keto-5α-abiraterone...
-
medications in
clinical practice.
Compared to the second-generation NSAAs,
enzalutamide and apalutamide,
bicalutamide has
inferior potency and
efficacy but similar...
-
structure to nilutamide,
which is
related to flutamide, bicalutamide, and
enzalutamide, all of
which are
NSAAs similarly. RU-58841 can be
synthesized either...
